Long-term safety of the Eversense® CGM system: PMCF registry

被引：0
|
作者：
Kaufman, F. R. [1 ]
Tweden, K. [1 ]
Haridas, H. [1 ]
Carlson, G. [2 ]
机构：
[1] Senseonics Inc, Germantown, MD USA
[2] Carlson Consulting, Oakland, CA USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
891
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [1] Post Market Clinical Follow-Up (PMCF) Registry to Demonstrate the Long Term Safety of the Eversense CGM System
    Carlson, Grace
    Tweden, Katherine S.
    Mdingi, Colleen
    Haridas, Haritha
    [J]. DIABETES, 2019, 68
  • [2] LONG-TERM SAFETY EVALUATION OF THE 90-DAY EVERSENSE CGM SYSTEM IN THE USPOST APPROVAL SETTING
    Latif, K.
    Warren, M.
    Oiknine, R.
    Mann, P.
    Tweden, K.
    Kaufman, F.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A156 - A156
  • [3] THE PROMISE STUDY: AN EVALUATION OF THE SAFETY AND ACCURACY OF THE NEXT GENERATION 180-DAY LONG-TERM IMPLANTABLE EVERSENSE CGM SYSTEM
    Garg, S.
    Liljenquist, D.
    Bode, B.
    Christiansen, M.
    Bailey, T.
    Brazg, R.
    Denham, D.
    Chang, A.
    Akturk, H.
    Dehennis, A.
    Tweden, K.
    Kaufman, F.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A36 - A37
  • [4] Evaluation of accuracy and safety of the next generation 180-day long-term implantable Eversense CGM system: the PROMISE Study
    Garg, S.
    Liljenquist, D.
    Bode, B.
    Christiansen, M.
    Bailey, T.
    Brazg, R.
    Denham, D.
    Chang, A. R.
    Akturk, H.
    Dehennis, A.
    Tweden, K. S.
    Kaufman, F. R.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 123 - 124
  • [5] Evaluation of the Next Generation 180-Day Long-Term Implantable Eversense CGM System: PROMISE Study
    Garg, Satish K.
    Liljenquist, David R.
    Bode, Bruce W.
    Christiansen, Mark P.
    Bailey, Timothy S.
    Brazg, Ronald L.
    Denham, Douglas S.
    Chang, Anna
    Akturk, Halis K.
    Dehennis, Andrew D.
    Tweden, Katherine
    Kaufman, Francine R.
    [J]. DIABETES, 2021, 70
  • [6] Safety of Microdose Dexamethasone Acetate in the Eversense Long-Term Implantable Continuous Glucose Monitoring System
    Kelley, E. L.
    Haridas, Haritha
    Lorenz, Carrie
    [J]. DIABETES, 2018, 67
  • [7] Modeling and Simulation of the Implantable Eversense CGM System
    Campos-Nanez, Enrique
    Chen, Oliver
    Dehennis, Andy
    Breton, Marc D.
    Kovatchev, Boris P.
    [J]. DIABETES, 2017, 66 : A246 - A246
  • [8] ACCURACY OF THE EVERSENSE CGM SYSTEM OVER MULTIPLE CYCLES
    Tweden, K.
    Deiss, D.
    Nuthakki, S.
    Nguyen, M.
    Kaufman, F.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A144 - A144
  • [9] Feasibility of Extended Calibration Intervals with a Long-Term, Implantable CGM System
    Gupta, Piyush
    Butler, Anthony
    Bertsch, Krista
    Jones, Hannah
    Lee, Melissa H.
    Obeyesekere, Varuni R.
    Martha, Sandra L.
    Jenkins, Alicia
    Oneal, David N.
    [J]. DIABETES, 2020, 69
  • [10] Long-term safety of growth hormoneA combined registry analysis
    Stochholm, Kirstine
    Kiess, Wieland
    [J]. CLINICAL ENDOCRINOLOGY, 2018, 88 (04) : 515 - 528
12345